IL236549A0 - Antibodies to a beta c-terminal or central epitope and uses thereof - Google Patents

Antibodies to a beta c-terminal or central epitope and uses thereof

Info

Publication number
IL236549A0
IL236549A0 IL236549A IL23654915A IL236549A0 IL 236549 A0 IL236549 A0 IL 236549A0 IL 236549 A IL236549 A IL 236549A IL 23654915 A IL23654915 A IL 23654915A IL 236549 A0 IL236549 A0 IL 236549A0
Authority
IL
Israel
Prior art keywords
terminal
beta antibodies
central epitope
epitope
central
Prior art date
Application number
IL236549A
Other languages
English (en)
Hebrew (he)
Original Assignee
Wyeth Llc
Janssen Alzheimer Immunotherap
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc, Janssen Alzheimer Immunotherap filed Critical Wyeth Llc
Publication of IL236549A0 publication Critical patent/IL236549A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL236549A 2012-07-03 2015-01-01 Antibodies to a beta c-terminal or central epitope and uses thereof IL236549A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261667891P 2012-07-03 2012-07-03
PCT/US2013/046399 WO2014007982A2 (en) 2012-07-03 2013-06-18 C-terminal and central epitope a-beta antibodies

Publications (1)

Publication Number Publication Date
IL236549A0 true IL236549A0 (en) 2015-02-26

Family

ID=49882576

Family Applications (1)

Application Number Title Priority Date Filing Date
IL236549A IL236549A0 (en) 2012-07-03 2015-01-01 Antibodies to a beta c-terminal or central epitope and uses thereof

Country Status (13)

Country Link
US (1) US20150353631A1 (enExample)
EP (1) EP2869846A4 (enExample)
JP (1) JP2015526409A (enExample)
KR (1) KR20150036163A (enExample)
CN (1) CN105579061A (enExample)
AU (1) AU2013287119A1 (enExample)
BR (1) BR112014033066A2 (enExample)
CA (1) CA2877516A1 (enExample)
HK (1) HK1208810A1 (enExample)
IL (1) IL236549A0 (enExample)
MX (1) MX2014015744A (enExample)
RU (1) RU2014153675A (enExample)
WO (1) WO2014007982A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3078121A1 (en) * 2013-09-13 2015-03-19 Beigene Switzerland Gmbh Anti-pd1 antibodies and their use as therapeutics and diagnostics
KR102130600B1 (ko) 2014-07-03 2020-07-08 베이진 엘티디 Pd-l1 항체와 이를 이용한 치료 및 진단
BR112017001385B1 (pt) 2014-07-22 2023-12-05 Cb Therapeutics, Inc. Anticorpo isolado ou fragmento do mesmo que liga a pd-1, uso deste, composição, polinucleotídeo isolado e vetor de expressão
ES2987034T3 (es) 2014-08-05 2024-11-13 Apollomics Inc Anticuerpos anti-PD-L1
US20180344881A1 (en) * 2015-11-20 2018-12-06 Navidea Biopharmaceuticals, Inc. Formulations for 2-heteroaryl substituted benzofurans
KR102799807B1 (ko) * 2015-12-30 2025-04-24 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
CN105542005B (zh) * 2016-02-03 2018-11-09 大连理工大学 一种抗人淀粉样β肽的纳米抗体及其应用
CN109475536B (zh) 2016-07-05 2022-05-27 百济神州有限公司 用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合
ES2971881T3 (es) 2016-08-19 2024-06-10 Beigene Switzerland Gmbh Combinación de zanubrutinib con un anticuerpo anti-cd20 o anti-pd-1 para su uso en el tratamiento del cáncer
US11555038B2 (en) 2017-01-25 2023-01-17 Beigene, Ltd. Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
US11597768B2 (en) 2017-06-26 2023-03-07 Beigene, Ltd. Immunotherapy for hepatocellular carcinoma
WO2019108795A1 (en) 2017-11-29 2019-06-06 Beigene Switzerland Gmbh Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
CN116348487A (zh) 2020-07-23 2023-06-27 欧萨尔普罗席纳有限公司 抗淀粉样β抗体
CN118382636A (zh) 2021-12-17 2024-07-23 豪夫迈·罗氏有限公司 一种用于检测淀粉样蛋白β42(Aβ42)的新抗体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9125798A (en) * 1997-08-28 1999-03-16 University Of Washington Specific saccharide compositions and methods for treating alzheimer's disease and other amyloidoses
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
SK288723B6 (sk) * 2000-02-24 2020-01-07 Univ Washington Farmaceutický prostriedok a použitie tohto farmaceutického prostriedku
TWI255272B (en) * 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
WO2005018424A2 (en) * 2003-08-18 2005-03-03 Research Foundation For Mental Hygiene, Inc. Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
AR051800A1 (es) * 2004-12-15 2007-02-07 Wyeth Corp Anticuerpos a beta usados en mejorar la cognicion
US20060210557A1 (en) * 2005-01-28 2006-09-21 Donna Luisi Stabilized liquid polypeptide formulations
MY167887A (en) * 2005-12-12 2018-09-26 Ac Immune Sa A beta 1-42 specific monoclonal antibodies with therapeutic properties
US20100239570A1 (en) * 2007-09-13 2010-09-23 Roger Nitsch Moncolonal amyloid beta (abeta) - specific antibody and uses thereof
WO2011133919A1 (en) * 2010-04-22 2011-10-27 Janssen Alzheimer Immunotherapy Use of tau to monitor immunotherapy
WO2011106732A1 (en) * 2010-02-25 2011-09-01 Wyeth Llc Pet monitoring of ab-directed immunotherapy

Also Published As

Publication number Publication date
MX2014015744A (es) 2015-06-05
BR112014033066A2 (pt) 2017-08-01
HK1208810A1 (en) 2016-03-18
EP2869846A2 (en) 2015-05-13
KR20150036163A (ko) 2015-04-07
AU2013287119A1 (en) 2015-01-22
WO2014007982A2 (en) 2014-01-09
US20150353631A1 (en) 2015-12-10
WO2014007982A3 (en) 2014-04-03
CN105579061A (zh) 2016-05-11
CA2877516A1 (en) 2014-01-03
EP2869846A4 (en) 2016-01-13
RU2014153675A (ru) 2016-08-27
JP2015526409A (ja) 2015-09-10

Similar Documents

Publication Publication Date Title
IL287270A (en) Anti-psgl-1 antibodies and their use
IL236549A0 (en) Antibodies to a beta c-terminal or central epitope and uses thereof
IL256716A (en) Antibodies against hla–b*27 and their uses
ZA201407927B (en) Anti-egfr antibodies and uses thereof
IL240443A0 (en) Antibodies against tnf-a with a high level of galactosylation and their uses
SG11201504764SA (en) Anti-human b7-h4 antibodies and their uses
IL254416A0 (en) Anti-asic1 antibodies and their uses
PL2831117T3 (pl) Przeciwciała anty-TLR4 i ich zastosowania
IL240440A0 (en) Antibodies against her2 with a high level of galactosylation and their uses
ZA201408213B (en) Anti-transglutaminase 2 antibodies
SG11201508875TA (en) Mab 2 anti-met antibody
EP2804876A4 (en) NEW ANTIBODIES
GB201208372D0 (en) Antibodies and uses thereof
GB201209584D0 (en) Modified antibodies
SG2013064282A (en) Mab 2 anti-met antibody